The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Hereditary Angioedema Therapeutics Market By 2030?
The hereditary angioedema therapeutics market has exhibited substantial growth in recent years. Its valuation is projected to increase from $7.77 billion in 2025 to $9.27 billion in 2026, at a compound annual growth rate (CAGR) of 19.3%. Historically, this market’s expansion can be ascribed to factors such as limited awareness about hae, a dependency on hospital-based therapy, fewer approved therapeutic options, the reliance on intravenous administration, and low prevalence diagnosis rates.
The hereditary angioedema therapeutics market is anticipated to experience substantial growth over the next few years. It is projected to reach $19.03 billion by 2030, achieving a compound annual growth rate (CAGR) of 19.7%. This expansion during the forecast period can be attributed to the rise of recombinant C1 esterase inhibitors, the adoption of subcutaneous delivery methods, increased usage of prophylactic therapy, the broadening of specialty pharmacy channels, and greater investment in rare disease research. Significant trends for this period encompass the development of personalized therapies, an increase in orphan drug approvals, ongoing advancements in subcutaneous drug delivery, the emergence of on-demand treatment options, and the expansion of hospital and retail pharmacy networks.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
What Market Drivers Are Helping Shape The Hereditary Angioedema Therapeutics Market Expansion?
The rising healthcare expenditure is anticipated to foster the development of the hereditary angioedema therapeutics market moving forward. Healthcare expenditure signifies the cumulative amount of resources, including financial means, dedicated to healthcare products and services within a specific timeframe in a particular geographic region. Elevated healthcare spending enables increased allocation to research and development initiatives focused on unraveling the fundamental causes of hereditary angioedema and pioneering advanced therapeutic solutions. For example, in June 2025, the US-based federal agency, Centers for Medicare & Medicaid Services (CMS), indicated that the National Health Expenditure (NHE) rose by 7.5% to $4.9 trillion in 2023, which is $14,570 per person, and represented 17.6% of the Gross Domestic Product (GDP). Hospital spending experienced a 10.4% increase, reaching $1,519.7 billion in 2023, which was a faster rate compared to the 3.2% growth recorded in 2022. Thus, the escalating healthcare expenditure is stimulating the growth of the hereditary angioedema therapeutics market.
What Are The Core Segment Classifications In The Hereditary Angioedema Therapeutics Market?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-Demand
Which Trends Are Shaping The Hereditary Angioedema Therapeutics Market Landscape?
Leading companies in the hereditary angioedema (HAE) therapeutics market are developing innovative treatments, such as oral plasma kallikrein inhibitors, to improve patient management and offer effective, on-demand options for relieving HAE attacks, thereby enhancing overall patient outcomes and quality of life. Oral plasma kallikrein inhibitors are medications taken by mouth that inhibit the enzyme plasma kallikrein, helping to control and reduce the severity of hereditary angioedema attacks. For example, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, received US Food and Drug Administration approval for its New Drug Application for Sebetralstat, aiming to provide HAE patients with a more convenient, non-invasive treatment alternative to intravenous or subcutaneous medications. This solution addresses the growing demand for rapid, effective oral treatments that can be administered instantly during an hereditary angioedema attack.
Which Companies Form The Competitive Landscape Of The Hereditary Angioedema Therapeutics Market?
Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.
Access The Complete Hereditary Angioedema Therapeutics Market Report:
Which Region Is The Dominant Market In The Hereditary Angioedema Therapeutics Market?
North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Hereditary Angioedema Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2026, By The Business Research Company
Hereditary Angioedema Therapeutics Market Report 2026
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Angina Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model